Abstract:Chimeric antigen receptor (CAR) T-cell therapy has proven a breakthrough in cancer treatment in the last decade, giving unprecedented results against hematological malignancies. All approved CAR T-cell products, as well as many being assessed in clinical trials, are generated using viral vectors to deploy the exogenous genetic material into T-cells. Viral vectors have a long-standing clinical history in gene delivery, and thus underwent iterations of optimization to improve their efficiency and safety. Nonetheless, their capacity to integrate semi-randomly into the host genome makes them potentially oncogenic via insertional mutagenesis and dysregulation of key cellular genes. Secondary cancers following CAR T-cell administration appear to be a rare adverse event. However several cases documented in the last few years put the spotlight on this issue, which might have been underestimated so far, given the relatively recent deployment of CAR T-cell therapies. Furthermore, the initial successes obtained in hematological malignancies have not yet been replicated in solid tumors. It is now clear that further enhancements are needed to allow CAR T-cells to increase long-term persistence, overcome exhaustion and cope with the immunosuppressive tumor microenvironment. To this aim, a variety of genomic engineering strategies are under evaluation, most relying on CRISPR/Cas9 or other gene editing technologies. These approaches are liable to introduce unintended, irreversible genomic alterations in the product cells. In the first part of this review, we will discuss the viral and non-viral approaches used for the generation of CAR T-cells, whereas in the second part we will focus on gene editing and non-gene editing T-cell engineering, with particular regard to advantages, limitations, and safety. Finally, we will critically analyze the different gene deployment and genomic engineering combinations, delineating strategies with a superior safety profile for the production of next-generation CAR T-cell.

Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance

Genetically engineered T cells for cancer immunotherapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Advances in cell therapy: progress and challenges in hematological and solid tumors

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer

Engineering immune-evasive allogeneic cellular immunotherapies

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

CAR immune cells: design principles, resistance and the next generation

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Engineering strategies to safely drive CAR T-cells into the future

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Engineering Enhanced CAR T-cells for Improved Cancer Therapy.

Tuning CAR T-cell therapies for efficacy and reduced toxicity